Skip to main content

Table 2 Recommendations for non-medical paediatric biosimilar switching

From: Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis

Recommendations for non-medical paediatric biosimilar switching
- Adequate biosimilar teaching for all staff
- A coherent message from all members of the team (medical, nursing, pharmacy, others)
- Written and verbal patient education prior to switching
- Disease and medication specific information to be provided to families
- Honest and balanced yet positive framing of information
- Detailed information on practical aspects of the biosimilar including device types, additives (including preservatives) and delivery logistics
- Information to be written and endorsed by familiar treating team members rather than anonymous administrators/pharmacy